Trial of YH32364 for EGFR-positive solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer listed in the trial, like head and neck, lung, esophageal, or others.
- Your tumor must show high levels of EGFR protein, as determined by a special test.
- You must be able to perform daily activities with little or no help (ECOG 0 or 1).
- You must have at least one tumor that can be measured with a scan.
- You must not have certain other health issues, like uncontrolled brain metastases, recent heart problems, or active infections.
- Women who are pregnant or breastfeeding cannot participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
This trial tests a new drug called JH021 in people with advanced solid tumors or a specific type of lung cancer. The goal is to see if it can help when other treatments have stopped working.
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
This study tests a new drug called JY016 for people with advanced solid tumors that have a protein called EGFR on their surface. The drug aims to help the immune system attack the cancer cells. It may be an option if standard treatments have stopped working or aren't suitable.
This trial tests a new targeted drug (cetuximab β) combined with radiation and chemotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.